SPOT-it™ SCID XLA
SCID and X-linked Agammaglobulinemia (XLA) Newborn Screening
Key Facts
About ImmunoIVD
ImmunoIVD is a commercial-stage diagnostics company and a market leader in Europe for newborn screening assays targeting SCID, SMA, and XLA. The company leverages a proprietary qPCR-based platform, SPOT-it™, which offers a simplified, equipment-light workflow using pre-filled reagent plates, making it highly suitable for national screening programs. With products integrated into multiple European national screening programs since 2016 and screening over one million newborns annually, ImmunoIVD has established a strong commercial footprint. The company is privately held, emphasizes research-driven innovation, and maintains a focus on quality and customer support, as evidenced by its ISO certifications and ESG recognition.
View full company profile